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 Objective To evaluate the clinical outcome and safety of stereotactic 
ablative radiotherapy for medically inoperable stage I non–
small-cell lung carcinoma. 
 Design Retrospective case series.
 Setting Pamela Youde Nethersole Eastern Hospital, Hong Kong.
 Patients All patients with medically inoperable stage I non–small-cell 
lung carcinoma receiving stereotactic ablative radiotherapy 
since its establishment in 2008.
 Main outcome measures Disease control rate, overall survival, and treatment toxicities.
 Results Sixteen stage I non–small-cell lung carcinoma patients underwent 
the procedure from June 2008 to November 2011. The median 
patient age was 82 years and the majority (81%) had moderate-to-
severe co-morbidity based on the Adult Comorbidity Evaluation 
27 index. With a median follow-up of 22 months, the 2-year 
primary tumour control rate, disease-free survival and overall 
survival rates were 91%, 71% and 87%, respectively. No grade 
3 (National Cancer Institute Common Terminology Criteria for 
Adverse Events) or higher treatment-related complications were 
reported. 
 Conclusion Stereotactic ablative radiotherapy can achieve a high degree of 
local control safely in medically inoperable patients with early 
lung cancer.
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Introduction
Conventional radiotherapy (RT) has been regarded as an inferior substitute to surgery 
in early stage non–small-cell lung cancer because of its lower rates of local control and 
overall survival (OS) compared to lobectomy with systematic lymph node dissection. Its 
reported median local failure rate was 40%, and the 3-year OS and cause-specific survival 
rates were reported to be 34 and 39%, respectively.1 On the contrary, surgery offered 
better survival outcomes in stage I disease with 5-year OS rates generally being greater 
than 50% (52-89%).2-5 While inferior OS in these case series can be partially explained by 
selection biases, inferior local control can be attributed to factors like inadequate radiation 
dose, inaccurate patient setup, suboptimal treatment verification, and failure to precisely 
account for respiratory motion. 
 With the advances in technology, new systems like Active Breathing Coordinator 
(Elekta, Stockholm, Sweden) or Real Time Position Management (Varian Medical Systems, 
Palo Alto [CA], US) are now available to take account of respiratory motion. Systems like 
ExacTrac (BrainLAB, Heimstetten, Germany) or On-board Imager (Varian Medical Systems) 
allow a more accurate setup and verification before treatment. Integrating these new 
systems allows higher doses and greater-precision RT to be delivered into smaller volumes 
than conventional techniques. These elements are all integral parts of stereotactic ablative 
radiotherapy (SABR). 
New knowledge added by this study
• Stereotactic ablative radiotherapy is a safe and effective novel technique for early stage 
medically inoperable lung cancer in our locality, and is tolerated even by elderly patients with 
multiple co-morbidities.
Implications for clinical practice or policy
• Patients with early stage non–small-cell lung cancer but having high surgical risks should be 
assessed by clinical oncologists to consider offering stereotactic ablative radiotherapy.
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 In the early 1990s, Lax et al6 and Blomgren et al7 
extrapolated the concept of stereotactic radiosurgery 
in the treatment of intracranial neoplasm to 
extracranial sites like liver and lung with encouraging 
results. The term ‘stereotactic body radiotherapy’ was 
coined to describe the precise delivery of radiation 
beams to body parts using a three-dimensional 
coordinated systems with reference to a ficidual 
marker that can be readily detected by imaging 
systems.8 Its synonym, stereotactic ablative body 
radiotherapy (SABR, pronounced as ‘SAY-BER’) has 
recently been advocated because the term ‘ablation’ 
can more accurately reflect the ultra-high radiation 
dose delivered in each fraction of radiation treatment, 
so as to overwhelm the normal cellular repair 
mechanisms and ‘ablate’ the tumour and adjacent 
tissues.9 The utilisation of SABR has bloomed in the 
past decade, but is still an evolving technique and 
more experience and clinical data are required. 
 In the Pamela Youde Nethersole Eastern 
Hospital, the SABR programme was established in 
June 2008, and by November 2011, 16 patients with 
early stage medically inoperable lung cancer were 
treated with this technique. This study aimed to 
evaluate treatment outcomes and safety of SABR in 
this population. 
Methods
All 16 patients treated with SABR were considered to 
have inoperable disease either because of inadequate 
pulmonary reserve (the forced expiratory volume in 
1 second being <1.5 L) or high surgical risks due to 
their pre-morbid status and concomitant illnesses. 
All patients had American Joint Committee on 
Cancer Stage I disease (7th ed) based on computed 
tomography (CT) of the thorax and abdomen 
and/or 18-fluorodeoxyglucose positron emission 
tomography (FDG-PET). Histological confirmation 
was also preferred but not mandatory. 
Radiotherapy treatment planning and delivery
The planning and delivery of the high-dose, high-
precision RT adhered to the recommendations of the 
European Organization for Research and Treatment 
of Cancer and the International Atomic Energy 
Agency.10-12 
 In brief, patients were immobilised by an 
alpha-cradle over the shoulders and back, with arms 
well-supported and holding a T-bar superior to the 
patient’s head. Imaging and motion characterisation 
were performed by four-dimensional CT (4DCT; 
General Electric Medical System, Waukesha [WI], 
US). A reflective marker was placed on the abdomen 
of the patient, and the breathing pattern was 
video-monitored by the Varian Real-time Position 
Management System (Varian Medical Systems). 
	 目的	 評核立體定位放射治療於不適宜手術的早期肺癌患者
的初步成效及安全性。
	 設計	 回顧病例系列研究。
	 安排	 香港東區尤德夫人那打素醫院。
	 患者	 自2008年開始所有接受立體定位放射治療的第一期非
小細胞肺癌但不適宜手術的病人。
	主要結果測量	 病灶控制率、整體存活率和治療副作用。
	 結果	 2008年6月至2011年11月期間，共16位第一期非小細
胞肺癌病人接受立體定位放射治療。病人年齡中位數 
為82歲，以成人合併症評估27為標準，大部份（81%）
病人都屬於中至高度合併症患者。研究追蹤期中位數
為22個月，兩年病灶控制率達91%，而兩年整體及無
疾病存活率分別為87%及71%，而治療並沒有引致等
級三（美國國家癌症研究院不良事件常用術語標準）
或以上的嚴重副作用。
	 結論	 立體定位放射治療於不適宜手術之早期肺癌患者屬安
全及有效。
不適宜手術的早期肺癌病人接受立體定位 
放射治療：初期成效
Patients were instructed to breathe in a quiet and 
consistent manner. Once a regular breathing pattern 
was achieved, a contrast 4DCT with 2.5-mm slice 
thickness was obtained from the level of cricoid 
to the second lumbar vertebra; CT datasets for 10 
phases spanning the respiratory cycles were then 
generated. 
 The gross tumour volume (GTV) was delineated 
in the ‘pulmonary’ window, with window width of 1600 
and level of -600. The internal target volume (ITV) was 
derived by contouring the lesion in the maximum 
projection intensity dataset or by summation of the 
GTVs in all 10 breathing phases. The ITV was the 
same as the clinical target volume, ie, no microscopic 
margin was added. A margin of 8 mm was added to 
the ITV to form the planning target volume (PTV) 
so as to account for the setup errors and the intra-
fractional movement. 
 A three-dimensional conformal RT technique 
was used. At least nine non-opposing fields were 
used to generate satisfactory treatment plans, and 
non-coplanar fields were used whenever indicated. 
The plan was normalised to the centre of the PTV. The 
dose was prescribed at 60 to 90% isodose level, and 
the appropriate prescription dose level was chosen 
where 95% PTV was covered by the prescription 
isodose and 99% PTV received at least 90% of 
the prescription dose. The planning criteria were 
similar to those published in the Radiation Therapy 
Oncology Group trial 0236.13 
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 Treatment planning was performed using the 
Varian Eclipse treatment planning system (Varian 
Medical Systems). Dose calculation was performed 
using a Pencil Beam Algorithm (PCB) without tissue 
heterogeneity correction before June 2009, and was 
later changed to an Anisotropic Analytic Algorithm 
(AAA, version 8.6) with tissue heterogeneity 
correction.
 Image-guided RT was employed to ensure 
high-precision delivery. Patients were set up with 
skin marks to start with, followed by on-board kilo-
voltage orthogonal imaging with the thoracic spine 
as the volumetric fiducial. Topographic images were 
then obtained by cone beam computed tomography 
(CBCT) and the tumour target itself served as the 
fiducial. Registration of the CBCT images to the 
planning of CT was performed, and automated to 
make corrections. The quality of the matching was 
crosschecked by clinical oncologists. ‘Couch shift’ 
was applied if the deviation in any direction was 
greater than 2 mm. The CBCT was repeated after 
treatment to assess the intra-fractional movement 
and for future setup margin modification, if indicated. 
 There were two different prescription dosages 
to the PTV. For peripheral lesions that were located 2 
cm in any direction beyond the proximal bronchial 
tree (including the trachea, carina, and major lobar 
bronchi), 60 Gray (Gy) in three fractions were 
delivered over 2 weeks for the PCB dose calculation 
algorithm and 54 Gy in three fractions for AAA. For 
centrally located lesions (within 2 cm from proximal 
bronchial tree), 50 Gy was given in five fractions over 
2 weeks. Each fraction was delivered at least 48 hours 
apart. Thirty minutes before each treatment, patients 
received 4-mg dexamethasone to reduce the risk of 
radiation pneumonitis. A typical dose colour wash 
and its beam geometry are shown in Figure 1. 
 Patients were assessed for acute untoward 
effects 2 weeks post-SABR. They were then assessed 
clinically every 3 to 4 months in the first 2 years and 
then every 6 months thereafter. Whenever possible, 
a follow-up CT thorax was performed at the third-, 
sixth-, and twelfth-month post-SABR. Other relevant 
investigations were arranged at the discretion of the 
clinicians. 
 Controlled primary disease was defined as 
per the Green’s criteria,11,14 which referred to the 
complete disappearance of all evidence of disease, 
FIG 1.  Typical beam geometry and dose colour wash of stereotactic ablative radiotherapy
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or that the residual radiographic abnormalities 
assessed by thoracic CT at the third- or sixth-month 
post-RT had remained stable for another 6 months. 
If serial CT scans were not available, local failure was 
classified if more than 20% enlargement of the initial 
tumour was noted. Local-regional failure referred 
to the emergence of new lesions within the same 
lobe or occurrence of malignant hilar or mediastinal 
lymphadenopathy. Treatment-induced toxicities 
were graded according to the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (NCI-CTCAE) version 3.0. Survival time was 
measured from the date of RT to the date of death or 
last assessment. Local control and survival rates were 
determined by the Kaplan-Meier method, using the 
Statistical Package for the Social Sciences (Windows 
version 15.0; SPSS Inc, Chicago [IL], US). 
Results
From June 2008 to November 2011, 16 lung cancer 
patients were treated with SABR. Among patients still 
alive (n=14) in December 2011 (the cut-off month), the 
median follow-up time was 22 months. The baseline 
characteristics of these patients are listed in the Table. 
All except one had undergone tumour biopsy, and in 
two the biopsies did not yield a definitive diagnosis 
(due to inadequate amount of tissue). 
 One patient was lost to follow-up 30 months 
after SABR, and two were not assessed for their 
radiological response; one of the latter died before 
the first CT and the other was not yet due for the first 
imaging. Among the 14 assessed patients, one primary 
tumour failure and two local-regional recurrences 
were detected in two individuals. One patient had 
recurrent disease within the same lobe while the 
primary lesion was under control; the tumour was 
33 mm and 60 Gy was delivered. The other patient 
achieved a partial response at the initial assessment 
but 11 months after completion of SABR, the primary 
tumour enlarged and metastasised to regional lymph 
nodes and pleura causing an ipsilateral pleural 
effusion. This was the only primary tumour failure 
and M1 disease noted to date; the patient had a 
20-mm tumour to which 54 Gy was delivered. The 
remaining patients had controlled local disease as 
per Green’s criteria. The estimated actuarial primary 
tumour control rate was 91% at 2 years. 
 Two cancer-unrelated deaths were also 
recorded. One patient with a history of acute 
myocardial infarction died of a recurrent cardiac 
infarct 82 days after SABR. The primary tumour was a 
left apical tumour and the cardiac dose was minimal 
(maximum point, 0.95 Gy and mean dose, 0.18 Gy). 
The other patient died 28 weeks after treatment. On 
her last admission, her chest radiograph revealed 
bilateral patchy infiltration, and the white cell count 
was mildly elevated. She was treated with antibiotics 
but developed sudden arrest before undergoing 
thoracic CT for further evaluation; her preliminary 
diagnosis was pneumonia. Her last CT thorax (2 
months prior to death) showed reduction in the size 
of the primary and no new lesions. The 2-year OS 
TABLE.  Patients and disease characteristics (n=16)
Patient/disease characteristic* Data
Median age (range) [years] 82 (71-90)
Sex 
Male 11
Female 5
Smoking status
Smokers/ex-smoker 13 (81%)
Never smoker 3 (19%)
Histology
Adenocarcinoma 9 (56%)
Squamous cell 3 (19%)
NSCLC, NOS 1 (6%)
Not available† 3 (19%)
ACE27 index
0/1 3 (19%)
2/3 13 (81%)
Performance status
0/1 10 (63%)
≥2 6 (37%)
Median (range) forced expiratory volume in 1 second (L) 1.45 (0.38-2.05)
Median (range) tumour dimension (mm) 21.5 (11-38)
T stage distribution
T1a 7 (44%)
T1b 3 (19%)
T2a 6 (37%)
Median (range) PTV volume (cc) 50 (18-96)
Metastatic workup modality
CT scan 2 (13%)
PET-CT 14 (87%)
No. of lesions
Peripheral lesion 12 (75%)
Central lesion 4 (25%)
Radiation dose fractionation
50 Gy in 5 fractions over 2 weeks‡ 4 (25%)
54 Gy in 3 fractions over 2 weeks‡ 6 (38%)
60 Gy in 3 fractions over 2 weeks§ 6 (38%)
* NSCLC, NOS denotes non–small-cell lung cancer (not otherwise specified), ACE27 Adult 
Comorbidity Evaluation 27, PTV planning target volume, CT computed tomography, and 
PET-CT positron emission tomography–computed tomography
† Biopsies of two patients were insufficient to reach pathological diagnosis; one patient 
refused biopsy, but serial CT images suggested lung cancer after multidisciplinary board 
assessment
‡ Dose calculated by Anisotropic Analytic Algorithm with tissue heterogeneity correction
§ Dose calculation by Pencil Beam Algorithm without tissue heterogeneity correction
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of the cohort was 87% and the 2-year disease-free 
survival was 71% (Fig 2). 
 The treatment toxicities were generally mild 
and transient. No severe (NCI-CTCAE ≥grade 3) 
pneumonitis was noted. One grade 2, acute, moist 
skin desquamation was detected 2 weeks post-SABR 
(Fig 3). No oesophagitis, chronic chest wall pain, or 
rib fractures were reported. 
Discussion
In this small case series, high rates of primary 
tumour control, disease-free survival, and OS with 
minimal side-effects were demonstrated. However, 
these results should be regarded as preliminary, 
due to the relatively short median follow-up (22 
months) and limited number of patients. The high 
local control rate concurred with rates of 80 to 98% 
reported in other series.10 One local series by Ng et 
al15 also reported favourable local-regional control 
in 20 medically inoperable patients treated with 
hypofractionated stereotactic RT. Only three local-
regional recurrences were detected after a median 
follow-up of 21 months. The 2-year disease-free 
survival was similar to ours (62% vs 71%). The median 
age of our cohort was 6 years older, but the 2-year 
OS was superior (87% vs 73%), and fewer distant 
metastases were found (1 vs 4). This could be due to 
differences in baseline medical conditions and the 
high percentage of our patient cohort staged by PET/
CT (87%), while only CT thorax and abdomen were 
used for staging in the series by Ng et al.15 These 
favourable early outcomes provide further local 
evidence to convince surgeons and physicians that 
SABR is a safe and effective option for patients with 
early stage lung cancer, especially if they are too frail 
to undergo surgical resection.
 Our current SABR programme offers many 
advantages over conventional RT. Radiobiologically, 
SABR gives a much higher biologically equivalent 
dose (BED) in an accelerated schedule. Higher BED 
and treatment acceleration has been shown to 
yield better survival outcomes.16-19 Technically, SABR 
incorporated improved immobilisation, image-
guided RT and tumour motion characterisation 
by 4DCT. Individualised and tighter margins can 
be tailored, allowing higher doses to be delivered 
more precisely. In terms of dosimetry, multiple 
non-coplanar fields in SABR plans achieved higher 
conformity and more rapid isotropic dose fall off. 
The dose within the tumour was not uniform, with 
higher doses within the centre of the tumour where 
potentially hypoxic cells resided. Logistically, the 
number of treatment fractions were greatly reduced 
from the conventional 30-35 to 3-5, and the overall 
treatment period was shortened from 6-7 down to ≤2 
weeks. This appeared especially favourable for frail 
elderly. From an economic perspective, SABR costs 
less than lobectomy, and appears to be more cost-
effective than conventional RT.20 
 Adult Comorbidity Evaluation 27 (ACE 27) is a 
commonly adopted co-morbidity assessment tool 
which grades 27 specific diseases into three different 
levels: mild (grade 1), moderate (grade 2), and severe 
(grade 3). Its prognostic role has been shown in various 
cancers.21,22 In all, 80% of the patients in our series had 
ACE 27 scores of 2 to 3. However, we still managed to 
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FIG 2.  Overall and disease-free survival for the 16 medically inoperable patients with 
stage I lung cancer
SABR denotes stereotactic ablative radiotherapy
FIG 3.  Transient wet desquamation 2 weeks after stereotactic 
body radiotherapy
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treat them effectively with minimal toxicity. Patients 
with multiple medical illnesses are usually managed 
conservatively because of co-existing inoperable 
lung cancer. With SABR eradicating the life-limiting 
factor, the co-existing illnesses may then deserve 
more aggressive interventions, for instance, coronary 
angioplasty may be offered to patients with ischaemic 
heart disease. 
 Currently, international series have 
demonstrated encouraging results for SABR in early 
lung cancer treatment. However, there are no phase 
III results to confirm its superiority over conventional 
RT or surgery. A European trial, ROSEL (ClinicalTrials.
gov ID NCT00687986), was conducted to randomise 
early stage lung cancer patients to undergo either 
surgery or SABR, but was abandoned due to poor 
recruitment. Though phase III data are absent, a Dutch 
population-based time-trend analysis demonstrated 
that with the introduction of SABR in Holland, the 
proportion of patients left untreated declined, there 
being a 16% absolute increase in RT usage, and OS 
improvement in the SABR-treated population.23 In 
a Japanese multi-institution study, Onishi et al19 
showed that survival rates in operable patients who 
received high BED (≥100 Gy) were excellent (88%) 
and appeared comparable to those of surgery. 
 Green’s criteria were used to evaluate the 
treatment outcome in our series. It is known that 
SABR generates intense fibrosis and pneumonitis 
surrounding tumour tissue. Instead of a complete 
resolution of the tumour, varying degrees of residual 
fibrosis and contracture were often observed (Fig 
4). Hence the terms complete or partial response 
as per RECIST (Response Evaluation Criteria in Solid 
FIG 4.  Tumour (a) before stereotactic ablative radiotherapy, the residual fibrosis, and contracture, and at (b) third-month and (c) 
12-month post-treatment
(a) (b) (c)
Tumors) could sometimes be arbitrary and observer-
dependent. While definite outcome assessment 
relied on histological evaluation, serial scans 
appeared to be a more practical and non-invasive 
method for frail elderly. A supplementary PET scan 
could be especially helpful but costs could be a 
limiting factor. The natural history of the radiographic 
changes and functional imaging after SABR require 
further elucidation. 
 More clinical data are needed to address 
questions related to optimal dose fractionation, 
normal tissue constraints, applicability to more 
advanced stages of lung cancer etc. Improvements in 
technique and machines could further refine SABR. 
For instance, the use of volumetric-modulated arc 
therapy planning has been shown to significantly 
reduce the treatment time of SABR using conformal 
RT or intensity-modulated RT techniques.24 Such 
improvement can reduce patient discomfort, 
minimise potential intrafractional movement, and 
maximise machine efficiency. 
 The SABR technique is still in the early stage of 
development in Hong Kong and still lacks publicity. 
This is reflected by the relatively small number of 
patients referred to our centre in the past 3 years. The 
low patient volume could hamper the training and 
development of SABR. These encouraging outcomes 
should be trumpeted in the community so that more 
suitable patients can benefit. 
 In conclusion, SABR can achieve high local 
control rates safely in medically inoperable patients 
with early lung cancer. The technique should 
therefore be introduced to suitable patients as a 
viable alternative. 
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